Quality of life in psoriatic arthritis-Reference-Cited by-同舟云学术

Quality of life in psoriatic arthritis

Published:2018-04-30 Issue:5 Volume:14 Page:405-417
ISSN:1744-666X
Container-title:Expert Review of Clinical Immunology
language:en
Short-container-title:Expert Review of Clinical Immunology

Author:

Gudu Tania¹,Gossec Laure²

Affiliation:

1. Research Center of Rheumatic Diseases, Sf Maria Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania

2. Department of Rheumatology, Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique; AP-HP, Pitié Salpêtrière Hospital, Paris, France

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2018.1468252

Reference97 articles.

1. Development of the WHOQOL: Rationale and Current Status

2. World Health Organization. International Classification Of Functioning, disability and health (ICF) [Internet]; [cited 2017 Dec 2]. Available from: www.who.int/classifications/icf/en/

3. Newer Biological Agents in Rheumatoid Arthritis

4. Spondyloarthritis Is Associated with Poor Function and Physical Health-Related Quality of Life

Cited by 142 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Psöriatik artritli hastalarda santral sensitizasyon ve ilişkili klinik değişkenlerin değerlendirilmesi;Balıkesir Medical Journal;2024-08-31

2. Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis;Drugs & Aging;2024-08

3. Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors;Drugs - Real World Outcomes;2024-07-31

4. Role of Anti-Inflammatory Diet and Fecal Microbiota Transplant in Psoriatic Arthritis;Clinical Therapeutics;2024-07

5. Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies;Rheumatology;2024-05-16